Strides Pharma Science Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Indicator Signals

Technical Trend Shift and Price Momentum

Strides Pharma Science Ltd (NSE: 688428) closed at ₹880.00 on 10 Feb 2026, up from the previous close of ₹863.90, marking a daily increase of 1.86%. The stock’s intraday range was ₹864.00 to ₹891.00, indicating some volatility but an overall upward bias. This price action coincides with a technical trend change from sideways to mildly bullish, primarily driven by the daily moving averages which have started to slope upwards, signalling potential short-term strength.

However, the weekly and monthly technical indicators present a more nuanced picture. The Moving Average Convergence Divergence (MACD) remains mildly bearish on both weekly and monthly charts, suggesting that momentum has not fully shifted to the bulls. Similarly, the Know Sure Thing (KST) indicator is mildly bearish on these timeframes, indicating that momentum oscillators are yet to confirm a sustained uptrend.

Relative Strength Index and Bollinger Bands Analysis

The Relative Strength Index (RSI) on weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This implies that the stock is neither overbought nor oversold, providing room for further price movement in either direction. Meanwhile, Bollinger Bands reveal a sideways pattern on the weekly scale but a bullish formation on the monthly scale, suggesting that longer-term volatility is expanding upwards, which could support higher prices if confirmed by volume.

Volume and Dow Theory Signals

On-balance volume (OBV) indicators show no discernible trend on weekly or monthly charts, indicating that volume has not decisively confirmed the price movements. Dow Theory assessments are mildly bearish on the weekly timeframe and show no clear trend monthly, reinforcing the mixed technical outlook. This divergence between price and volume signals warrants caution, as it may reflect a tentative market consensus on the stock’s direction.

Comparative Returns and Market Context

From a returns perspective, Strides Pharma has outperformed the Sensex over multiple horizons. The stock delivered an 18.01% return over the past year compared to the Sensex’s 7.97%, and an impressive 511.65% return over three years versus the Sensex’s 38.25%. Even over five years, Strides Pharma’s 115.89% gain significantly exceeds the Sensex’s 63.78%. However, the 10-year return of 77.62% trails the Sensex’s 249.97%, reflecting some longer-term underperformance.

Shorter-term returns show some volatility, with a 1-week gain of 5.31% outperforming the Sensex’s 2.94%, but a 1-month decline of 6.69% contrasting with the Sensex’s modest 0.59% rise. Year-to-date, the stock is down 2.48%, slightly worse than the Sensex’s 1.36% decline. These fluctuations highlight the stock’s sensitivity to sector-specific and broader market factors.

Mojo Score Upgrade and Market Capitalisation Insights

MarketsMOJO recently upgraded Strides Pharma’s Mojo Grade from Sell to Hold on 9 Feb 2026, reflecting an improved outlook based on technical and fundamental factors. The current Mojo Score stands at 56.0, signalling moderate confidence in the stock’s prospects. The Market Cap Grade is rated 3, indicating a mid-sized capitalisation within the Pharmaceuticals & Biotechnology sector.

This upgrade aligns with the mildly bullish technical trend and the stock’s relative outperformance over the medium term. However, the Hold rating suggests that investors should maintain a cautious stance, awaiting clearer confirmation from momentum indicators and volume trends before committing additional capital.

Moving Averages and Daily Price Action

The daily moving averages have turned mildly bullish, with the 20-day moving average crossing above the 50-day average in recent sessions. This crossover is often viewed as a positive signal for short-term momentum, potentially attracting momentum traders and short-term investors. The stock’s current price of ₹880.00 remains below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹551.00, indicating a recovery phase within a broader uptrend.

Investors should monitor whether the stock can sustain gains above the 200-day moving average, which would further validate the bullish shift. Conversely, failure to hold above key moving averages could signal a return to sideways or bearish conditions.

Sector and Industry Considerations

Strides Pharma operates within the Pharmaceuticals & Biotechnology sector, a space characterised by regulatory complexities, innovation cycles, and sensitivity to global health trends. The sector’s performance often diverges from broader market indices, influenced by drug approvals, patent expiries, and research and development outcomes.

Given the mixed technical signals and the Hold Mojo Grade, investors should weigh sector-specific developments alongside technical analysis. The stock’s recent mild bullish momentum may be supported by positive industry news or pipeline progress, but the absence of strong volume confirmation advises prudence.

Outlook and Investor Considerations

In summary, Strides Pharma Science Ltd is exhibiting early signs of a technical uptrend, supported by daily moving averages and a recent price uptick. However, the weekly and monthly momentum indicators such as MACD and KST remain mildly bearish, and volume-based signals have yet to confirm a decisive breakout. The stock’s relative outperformance over the past year and three years compared to the Sensex is encouraging, but short-term volatility and mixed signals warrant a balanced approach.

Investors should watch for confirmation of bullish momentum through sustained price action above key moving averages and improved volume trends. Monitoring sector developments and regulatory news will also be critical in assessing the stock’s medium-term potential. The current Hold rating from MarketsMOJO reflects this cautious optimism, suggesting that while the stock is no longer a sell, it has not yet reached a strong buy status.

For those considering exposure to the Pharmaceuticals & Biotechnology sector, Strides Pharma offers a compelling blend of growth potential and risk, but careful timing and ongoing technical analysis remain essential.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →